Lonza inks strategic long-term deal
Medarex has secured the option to use Lonza’s manufacturing services in the development and commercialisation of its therapeutic proteins and antibody drug conjugates.
Altus accuses Lonza of breaching contract
Altus Pharmaceuticals has terminated its contract with Lonza over an alleged breach in the agreement to provide active pharmaceutical ingredients (API) for Trizytek (liprotamase).
Lonza’s GS system wins Elusys anthrax Ab contract
Swiss life sciences solutions firm Lonza has been contracted by US biotechnology group Elusys Therapeutics to produce Anthim, its late stage Ab candidate treatment for anthrax infection.
Emerson wins Singapore bio plant contract
Industrial automation specialist Emerson Process Management has won the contract to help Swiss life sciences group Lonza design its new biopharmaceuticals plant in Singapore.
Robust demand helps Lonza meet mid-term goal
Lonza has felt “no negative impact” from the economic crisis and demand from clients remains strong, which will enable the company to post average growth in the high teens until 2013.
Lonza opens Guangzhou engineering services unit
Lonza hopes that the new business it has set up in China will help cement its position as a leading provider of services to the country’s pharmaceutical manufacturing sector.
Small molecules drive Lonza contract unit in 1H
Lonza of Switzerland is reaping the benefit of a shift away from bulk chemicals and towards custom manufacturing of high-value pharmaceuticals with a 13 per cent hike in sales in the first half of the year.
Lonza scores stem cell deal; builds facility
Lonza has scored a contract manufacturing agreement from Osiris
Therapeutics for its investigational adult stem cell therapy is
building a new facility to support future business activities in
Lonza looks to the future as it reveals 2007 profit hike
Lonza has revealed a profit hike for the full year of 2007,
reflecting the fruit of its "revised growth strategies"
across its business units, said the firm, which also announced its
"innovations" for future growth...
Lonza adds new expression media to portfolio
Swiss supplier and services provider Lonza has added another
product to its catalogue of cell culture media, the most recent
addition to the offering of its new bioscience unit.
Lonza pushes biopharma portfolio
Switzerland-based Lonza is establishing its biopharma portfolio
with the acquisition of Zyentia's Aggresolve technology this week.
Lonza leans towards highly potent APIs
Lonza is building a new plant in its home country to become the
only contract manufacturer with large-scale capacity for making
highly potent active pharmaceutical ingredients (APIs).
Lonza to combine microbial biopharma ops
Swiss contract manufacturer Lonza has decided to merge its US
microbial biopharma business activities in a single location, three
months after buying Cambrex's biopharma unit.
Lonza plans to commercially produce emerging class of drugs
Lonza is betting on the growth of antibody-drug conjugates as the
way-of-the-future cancer treatments by moving to large scale
production of the emerging drug class by 2008.
BMS extends large Lonza deal
Bristol-Myers Squibb (BMS) has extended its large contract
manufacturing arrangement with Lonza by four years.